Daunorubicin
Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib National Cancer Institute (NCI) | Phase 2 | B |
Cytosin-Arabinosid National Cancer Institute (NCI) | Phase 2 | B |
Gemtuzumab Ozogamicin M.D. Anderson Cancer Center | Phase 2 | CCC |
Fludarabine M.D. Anderson Cancer Center | Phase 2 | CCC |
Decitabine M.D. Anderson Cancer Center | Phase 2 | CCC |
Idarubicine M.D. Anderson Cancer Center | Phase 2 | CCC |
FILGRASTIM-SNDZ M.D. Anderson Cancer Center | Phase 2 | CC |
Same molecule, other indications
Daunorubicin is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →